The Lipid Paradox in Statin-Naïve Patients with a First ST-Segment Elevation Myocardial Infarction Treated with...

Area of Science:

• Cardiology
• Biochemistry
• Clinical Medicine

Background:

• The association between low admission low-density lipoprotein cholesterol (LDL-C) and adverse outcomes post-acute coronary syndrome (ACS) is known as the "lipid paradox."
• This paradox may be attributed to confounding factors rather than a causal relationship.
• This study specifically investigates the lipid paradox in patients who have not previously used statin medications.

Purpose of the Study:

• To examine the relationship between admission LDL-C levels and outcomes in statin-naïve patients following a first ST-segment elevation myocardial infarction (STEMI).
• To determine if low LDL-C is a marker of increased risk or a protective factor in this patient population.
• To clarify the role of confounding factors like age and frailty in the observed lipid paradox.

Main Methods:

• A cohort of 388 statin-naïve patients with a first STEMI, treated with primary percutaneous coronary intervention (PCI), was followed for up to five years.
• Admission LDL-C was analyzed both continuously and categorized into three groups (<100 mg/dL, 100-130 mg/dL, >130 mg/dL).
• All-cause mortality was assessed using Kaplan-Meier curves, Cox regression, restricted cubic splines, and landmark sensitivity analyses.

Main Results:

• Crude mortality was highest in the lowest LDL-C group (<100 mg/dL), with 20.0% mortality compared to 8.3% and 10.7% in higher LDL-C groups (p=0.014).
• Initially, LDL-C <100 mg/dL predicted higher mortality (HR 2.03). However, after adjustment for confounding factors, this association became non-significant (adjusted HRs 1.27-1.43).
• Independent predictors of death included older age, lower ejection fraction, and diabetes. Patients in the lowest LDL-C group also exhibited markers of frailty, such as lower albumin and higher CONUT scores.

Conclusions:

• In statin-naïve STEMI patients treated with primary PCI, the observed "lipid paradox" is likely due to confounding by age and frailty.
• Low admission LDL-C appears to signify a higher-risk patient phenotype rather than offering protection.
• These findings suggest that low admission LDL-C should not deter clinicians from initiating guideline-directed lipid-lowering therapy in STEMI patients.